Genmab — Januar 2021
-
Novartis 'not leaving any stone unturned' for Kesimpta, Leqvio as Entresto, Cosentyx drive growth https://www.fiercepharma.com/pharma/novartis-not-leaving-any-stone-unturned-for-kesimpta-leqvio-as-entresto-cosentyx-drive?utm_source=dlvr.it&utm_medium=twitter
-
JNJ analysts: Exploding sales for the cancer drugs Darzalex (daratumumab) and Imbruvica (ibrutinib) were a major factor in the strong performance https://www.thepharmaletter.com/article/j-j-exceeds-estimates-to-send-shares-higher . Genmab analysts: pffff, is that all??
-
from JNJ transcript https://news.alphastreet.com/johnson-johnson-jnj-q4-2020-earnings-call-transcript/ Our Oncology portfolio delivered another robust quarter with worldwide growth of 23.7%. DARZALEX continued its strong performance growing 49%, led by share gains globally with the US market share up about 4 points across all lines of therapy.
-
Furthermore, the US and European markets continue to exhibit increased adoption of the subcutaneous formulation launched in the second quarter as feedback continues to be very positive on the ease and reduced time to administer the new formulation. Also, we continue to advance the DARZALEX innovation pipeline with the recent US approval of DARZALEX FASPRO for the treatment of patients with newly diagnosed light chain amyloidosis.
-
God morgen.
-
Onsdagens aviser med Tryg, Mærsk og Danske Bank: https://www.proinvestor.com/investornyt/671481/onsdagens-aviser-med-tryg-maersk-og-danske-bank
-
Jeg er optimist - ja
mht tallene ved jeg godt at det er højt, men baserer det på at vi har set en øget stigningstakt i stedet for det modsatte. Er klar over at der skal komme en udflagning, men tror det bliver senere. Der kan også være en ekstra effekt når Coronaen slipper. Vil blive overrasket hvis guidingen i stedet ligger omkring 5,5. Men måske jeg er i den høje ende vi får se -
Aktier/tendens: Ambu står til at indtage hovedrolle i rødt markedhttps://www.proinvestor.com/investornyt/671490/aktier-tendens-ambu-star-til-at-indtage-hovedrolle-i-rodt-marked
-
Australia - In March 2021, the Pharmaceutical Benefits Advisory Committee (PBAC) will be meeting to consider a proposal to recommend adding ofatumumab (Kesimpta) https://msra.org.au/news/ofatumumab-up-for-pbs-inclusion/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind